Senate reauthorizes accelerated approval pathway for ALS therapies
The bill extends funding through 2031 for federal programs that support research into treatments for ALS and other neurodegenerative diseases, including grants from the National Institutes of Health and Food and Drug Administration plus a joint public-private partnership. Sen. Lisa Murkowski (R-AK) introduced the bill, which passed the Senate by voice vote in August 2026 with bipartisan support. The bill also requires the NIH to assess drug safety and efficacy when renewing grants, the FDA to publish five-year plans on fostering drug development, and federal agencies to report on the program's impacts.
Where it is in the process
Community vote
How readers of ThePolitibase feel about this bill. Reader sentiment only — not a scientific poll, and not a measure of public opinion.
District map
Sponsor
Cosponsors (15)
Activity timeline
2d ago
2d ago
Jul 16
Jul 16
Jul 16
Jun 17
Apr 30
Apr 30